FDA approval for ADHD drug

The US Food and Drug Administration has granted approval for Adzenys ER (amphetamine) extended-release oral suspension, from US modified-release drug specialist Neos Therapeutics.

Adzenys ER, for the treatment of attention deficit hyperactivity disorder (ADHD), will be commercially available in early 2018, the company noted. It will compete with Adderall XR (mixed amphetamine salts), which is marketed by Ireland-based pharma company Shire.